重组甘精胰岛素联合阿卡波糖和甘舒霖30R治疗2型糖尿病的比较被引量：2

导出

摘要选2型糖尿病患者68例,随机分为两组。治疗组,重组甘精胰岛素(长秀霖)(n=34);对照组,(甘舒霖30R胰岛素)(n=34)。分别采用每晚9点注射甘精胰岛素加阿卡波糖(三餐中嚼服)和甘舒霖30R早、晚餐前皮下注射。根据血糖水平调整胰岛素剂量,观察3个月治疗后,两组空腹血糖(FBG)、餐后2小时血糖(2hPBG)和糖化血红蛋白(HbA1c)无明显差异(P>0.05)。但甘精组低血糖发生率明显少于预混组(P<0.05),且体重无明显变化(P>0.05)。结论:甘精胰岛素联合阿卡波糖治疗2型糖尿病比较甘舒霖30R治疗T2DM均可有效降低血糖,对体重增加影响小,低血糖发生率低。

作者张晓丹宋路芹张胜男

机构地区吉林双鸭山市人民医院内分泌科

出处《实用糖尿病杂志》 2011年第2期35-36,共2页 Journal of Practical Diabetology

关键词重组甘精胰岛素阿卡波糖甘舒霖30R 2型糖尿病(T2DM)

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献3

1叶任高,陆再英主编..内科学[M].北京:人民卫生出版社,2004:1030.
2卜石,邢小燕,王娜,赵文惠,杨文英.长效胰岛素联合口服降糖药治疗2型糖尿病的疗效与安全性[J].中国循证医学杂志,2004,4(7):464-467. 被引量：157
3拜唐苹联合其他口服降糖药治疗2型糖尿病的有效性和安全性临床研究——多中心、非随机、开放性、自身对照研究[J].国际内分泌代谢杂志,2009,29(2):77-80. 被引量：11

二级参考文献15

1UK prospective Diabetes Study (UKPDS) Group. Lancet, 1998,352 : 837 -853. 被引量：1
2ADVANCE Collaborative Group,Patel A,MacMahon S,Chalmers J ,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med ,2008 ,358 :2560-2572. 被引量：1
3DECODE Study Group,the European Diabetes Epidemiology Group. Glucose tolerance and cardiovaseular mortality:eomparison of fasting and 2-hour diagnostic eriteria. Arch Intern Med ,2001,161:397-405. 被引量：1
4DECODA Study Group, International Diabetes Epidemiology Group. Cardiovascular risk profile assessment in glucose-intolerant Asian individuals-an evaluation of the World Health Organization two-step strategy:the DECODA Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia ). Diabet Med, 2002, 19: 549-557. 被引量：1
5Hanefeld M,Fischer S,Julius U ,et al. Risk factors for myocardial infarction and death in newly detected NIDDM:the Diabetes Intervention Study, 11-year follow-up. Diabetologia, 1996,39:1577-1583. 被引量：1
6Meigs JB ,Nathan DM ,Wilson PW,et al. Metabolic risk factors worsen continuously across the spectrum of non-diabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med, 1998, 128: 524-533. 被引量：1
7Rodriguez BL, Lau N, Burchfiel CM, et al. Glucose intolerance and 23- year risk of coronary heart disease and total mortality: the Honolulu Heart program. Diabetes Care ,1999 ,22 :1262-1265. 被引量：1
8Riddle MC,Rosenstock J,Gerich J.Insulin Glargine 4002 Study Investigators.The treat-to-target trial:randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients[J].Diabetes Care,2003; 26(11):3 080-3 086. 被引量：1
9HOE 901/3002 Study Group.Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes[J].Diabetes Care,2000; 23(8):1 130-1 136 被引量：1
10UKPDS Study Group.Stratton IM,Adler AI,Neil HAW,Matthews DR,Manley SE,Cull CA,Hadden D,Turner RC,Holman RR.Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes:prospective observational study (UKPDS 35) [J].BMJ,20 被引量：1